FineHeart ICOMS has raised capital in equity funds from a pool of six investors
FineHeart has raised capital in a series A financing. The funds, which have come from a total of six investors led by Broadview Ventures (Boston, USA), will be used to finance the development of FineHeart’s first product. In addition to Broadview Ventures, the financing included several new investors such as M Capital Partners, an independent private equity fund, Sofimac and Galia Gestion, well-known French regional equity funds and IRDInov, an inter-regional Seed Fund.
The patented FineHeart invention, the ICOMS (Implantable Cardiac Output Management System), is a novel, wirelessly powered, fully implantable mechanical circulatory support device that is able to optimize cardiac output while preserving the heart’s innate contractility. It is a game changing therapy for long term circulatory assistance in severe heart failure patients. FineHeart was founded by a team of four internationally renowned cardiac surgeons and cardiologists, led by Dr. Stéphane Garrigue (ICOMS Inventor) and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy, with a vision of making a miniaturized, fully implantable, pulsatile circulatory support system that would overcome many of the challenges associated with left ventricular assist devices (LVADs) currently in the market.
Oaklins’ team in France acted as the exclusive advisor of FineHeart during the fundraising transaction.
Talk to the deal team
Thibaut de Monclin
A group of Chilean investors has acquired Farmacias Ahumada
A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.Learn more
Shield Therapeutics has completed a fundraising
Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.Learn more
Haydale Graphene Industries has completed a fundraising
Haydale Graphene Industries PLC has raised funds to continue to develop the ongoing commercialization of its proprietary HDPlas® plasma functionalization process.Learn more